Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 2, 2007, Pages 267-273

  Dijkgraaf, Ingrid ^a   Kruijtzer, John A W ^b   Liu, Shuang ^c   Soede, Annemieke C ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Liskamp, Rob M J ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Alpha v beta 3 integrin receptor; Indium 111; Multimerisation; RGD peptides; SK RC 52 tumour

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ARGINYLGLYCYLASPARTIC ACID IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LABELING; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG UPTAKE; FEMALE; IC 50; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN TARGETING; STATISTICAL MODEL; TUMOR;

ANIMALS; DIMERIZATION; DRUG DELIVERY SYSTEMS; FEMALE; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33846422759     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0180-9     Document Type: Article

References (23)

1. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;32A:2423-2429
2. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-1875
3. Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castelman's disease. J Pathol 1997;183:44-50
4. PerezAtayde AR, Sallan SE, Tedrow U, Conners S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-821
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
6. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligands binding to integrins. J Biol Chem 2000;275:21785-21788
7. 3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997;36:1374-1389
8. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-54
9. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RDG peptides. Eur J Biochem 1992;210:911-921
10. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled alpha-v-beta-3 integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-6151
11. Johansson SMC, Arnberg N, Elofsson M, Wadell G, Kihlberg J. Multivalent HSA conjugates of 3′-sialyllactose are potent inhibitors of adenoviral cell attachment and infection. Chembiochem 2005;6:358-364
12. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-2794
13. Joosten JAF, Loimaranta V, Appeldoorn CCM, Haataja S, Ait El Maate F, Liskamp RMJ, et al. Inhibition of Streptococcus suis adhesion by dendritic galabiose compounds at low nanomolar concentration. J Med Chem 2004;47:6499-6508
14. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 2001;42:1519-1527
15. 3 integrin directed therapeutics. Bioconjugate Chem 2002;13:128-135
16. Maheshwari G, Brown G, Lauffenburger DA, Wells A, Griffith LG. Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci 2000;113:1677-1686
17. 3-integrin binding peptidomimetics for tumor targeting. Eur J Nucl Med Mol Imaging 2004;31 (Suppl 2):S281
18. 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjugate Chem 2001;12:559-568
19. 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707-1718
20. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem Eur J 2003;9:2717-2725
21. Vrasidas I, André S, Valentini P, Böck C, Lensch M, Kaltner H, et al. Rigified multivalent lactose molecules and their interactions with mammalian galectins: a route to selective inhibitors. Org Biomol Chem 2003;1:803-810
22. Kiessling LL, Pohl NL. Strength in numbers: non-natural polyvalent carbohydrate derivatives. Chem Biol 1996;3:71-77
23. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-212